7TM Pharma’s Progress Attracts EUR 19 million in a Series C Financing Round

7TM Pharma A/S announces the closing of a EUR 19 million Series C financing round. The round was led by LD Pensions in collaboration with Scottish Widows Investment Partnership and includes a significant commitment from existing investors, Alta Partners, Novo A/S, Index Ventures, Johnson & Johnson Development Corporation and Dansk Innovationsinvestering.

The capital raised will support current operations well into 2008. This includes clinical development through phase IIa proof-of-concept of the lead anti-obesity agents TM30338 and TM30339 as well as the initiation of development of further drug candidates emerging from 7TM Pharma's in-house discovery efforts. 7TM Pharma recently announced positive results from the company's clinical phase I/II study with TM30338, a dual Y2-Y4 receptor agonist for the treatment of obesity and related diseases.

For further information please contact:

Mette Kirstine Agger,

CEO

Tel: + 45 39 25 77 77

Email: agger@7tm.com

Or visit: www.7tm.com

Home > News & Events > News > 7TM Pharma’s Progress Attracts EUR 19 million in a Series C Financing Round
Last updated: 2006-04-21

The official Medicon Valley site is brought to you by the organisations Region Skåne and Copenhagen Capacity - in association with Medicon Valley Alliance

Contact:
Copenhagen Capacity,	tel: +45 33 22 02 22
Region Skåne,	tel: +46 (0)40 623 97 48

7TM Pharma A/S

7TM Pharma A/S is a privately held company, incorporated in 2000 as spin out from University of Copenhagen by internationally recognized pioneers in 7TM receptor research, Professor Thue W. Schwartz and Dr. Christian E. Elling alongside with industry-experienced Mette Kirstine Agger (CEO). The comp...